Funding
S Verstovsek has received consultancy fees from Celgene, Constellation Pharmaceuticals, Incyte, Novartis, Pragmatist, and Sierra Oncology; and research funding from Blueprint Medicines, Celgene, CTI BioPharma Corp, Genentech, Gilead Sciences, Incyte, Novartis, NS Pharma, Promedior, and Roche. HK Al-Ali has received honoraria from Novartis, Bristol Myers Squibb, and AbbVie; has received consultancy fees from Novartis, Bristol Myers Squibb, and AbbVie; and has received research funding from Incyte and Bristol Myers Squibb. J Mascarenhas has consultancy fees from Incyte, Kartos Therapuetics, Celgene, Bristol Myers Squibb, Constellation, CTI BioPharma Corp, Geron, AbbVie, Imago, Galecto, Karyopharm, GSK, Roche, Novartis, PharrmaEssentia; and research funding from Novartis, Roche,Merck, CTI BioPharma Corp, Incyte, Kartos Therapeutics, AbbVie, PharmaEssentia, Celgene, BristolMyers Squibb, and Geron. A Perkins has received consultancy fees from Novartis, Sierra Oncology, Abbvie, and CTI BioPharma Corp and has been paid to participate in a speaker’s bureau for Novartis. AM Vannucchi has received consultancy fees from; and has been paid to participate in a speaker’s bureau for Celgene, Incyte, Novartis, AbbVie, Blueprint Medicines, CTI BioPharma Corp, and Roche. S Mohan has received research funding Incyte, Karyopharm, Kartos Therapeutics, and Taiho. B Scott has received consultancy fees from CTI BioPharma Corp and Incyte. D Woszczyk has received research funding from AbbVie, Acerta, Astellas, Celgene, Janssen, Kartos Therapeutics, Roche, Sierra Oncology, and Telios Pharma. S Koschmieder has received research funding from Geron, Janssen, AOP Pharma, and Novartis, consulting fees from Pfizer, Incyte, Ariad, Novartis, AOP Pharma, Bristol Myers Squibb, Celgene, Geron, Janssen, CTI BioPharma Corp, Roche, Bayer, and PharmaEssentia; honoraria from Novartis, Bristol Myers Squibb/Celgene, Pfizer; travel and accommodation support from Alexion, Novartis, Bristol Myers Squibb, Incy
